This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Using PET Scans to Study Brain Receptor Occupancy of BIIB014 in Healthy Male Volunteers

This study has been completed.
Information provided by:
Biogen Identifier:
First received: September 17, 2007
Last updated: July 29, 2008
Last verified: July 2008
To establish the extent to which BIIB014, following 8 to 12 consecutive days of dosing at selected dose levels, occupies the brain's A2A receptors. Receptor occupancy will be assessed by PET scanning using a radiolabelled tracer.

Condition Intervention Phase
Healthy Drug: BIIB014 Other: [11C]SCH442416 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: An Open-Label, Positron Emission Tomography Study to Assess Adenosine A2A Brain Receptor Occupancy of BIIB014 at Multiple Dose Levels in Healthy Male Volunteers

Resource links provided by NLM:

Further study details as provided by Biogen:

Primary Outcome Measures:
  • PET scanning with [11C]SCH442416 of the putamen, caudate, nucleus accumbens, thalamus, and cerebellum. [ Time Frame: pre-dose and 24h following last dose ]

Secondary Outcome Measures:
  • Concentrations of BIIB014 and its N-acetyl metabolite will be measured in blood plasma [ Time Frame: up to 24h following last dose ]

Enrollment: 32
Study Start Date: September 2007
Study Completion Date: April 2008
Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Various protocol-specified doses of BIIB014 will be used (doses to be determined by PET scan results)
Drug: BIIB014
oral administration of BIIB014, given once daily for 8 to 12 consecutive days, at various doses as specified in protocol
Other: [11C]SCH442416
11C]SCH442416 is a radiolabelled tracer molecule that specifically binds to adenosine A2A sites and will be used to evaluate receptor occupancy. The target activity will be 370 MBq. [11C]SCH442416 will be administered IV as a bolus injection over 30 seconds following the start of each PET scan.

Detailed Description:

Subjects will be enrolled sequentially into cohorts of 2 to 4 subjects. PET scan results will determine the actual number of cohorts enrolled and the BIIB014 dose given to each subject. Since all enrolled subjects will be receiving BIIB014, this study is being listed as a 1-arm, Single Group study (actual study design is dose escalation).

Participating subjects will be required to reside in the clinical unit for 10 to 14 consecutive days. Participants will receive 1 oral dose of BIIB014 daily for 8 to 12 consecutive days. During the study, subjects will undergo 2 PET scans and 1 MRI. Frequent blood sample for pharmacokinetic assessments will also be performed.


Ages Eligible for Study:   25 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • BMI between 18.0 and 29.0 kg/m2
  • Willing to abstain from caffeine-containing products from 1 week prior to dosing until discharge from unit.
  • Willing and able to practice effective contraception until 2 months following last dose of study drug.

Exclusion Criteria:

  • History of severe allergic reactions or clinically significant allergies.
  • History of malignancy, excluding adequately treated basal cell carcinoma.
  • History of any clinically significant disease.
  • History of claustrophobia or any condition incompatible with MRI/PET scanning.
  • History of any exposure to ionizing radiation, with the exception of dental x-rays, within the 12 months prior to dosing.
  • Serious infection within the 4 weeks prior to dosing.
  • HbA1c > 6%, positive for Hepatitis C or Hepatitis B, presence of HIV or known exposure to HIV, positive G6PD assay, or any other clinically significant abnormal laboratory parameters at Screening.
  • Abnormal supine or standing blood pressure or orthostatic hypotension.
  • Any prior treatment with antipsychotic medications, dopamine antagonists, or dopaminergic agonists.
  • Treatment with any other investigational drug within 3 months prior to dosing.
  • Treatment with any prescription medications within 4 weeks prior to dosing.
  • History of drug or alcohol abuse within 1 year prior to dosing.
  • Current smoker or any tobacco use within 3 months prior to dosing.
  • Heavy caffeine consumption within 4 weeks prior to dosing.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00531193

United Kingdom
Research Site
London, United Kingdom
Sponsors and Collaborators
Study Director: Biogen Idec Cambridge, MA USA
  More Information

Responsible Party: Biogen Idec MD, Biogen Idec Identifier: NCT00531193     History of Changes
Other Study ID Numbers: 204HV101
EUDRACT 2007-001575-10
Study First Received: September 17, 2007
Last Updated: July 29, 2008

Keywords provided by Biogen:
Healthy male volunteers

Additional relevant MeSH terms:
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Vasodilator Agents
Purinergic P1 Receptor Agonists
Purinergic Agonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adenosine A2 Receptor Antagonists
Purinergic P1 Receptor Antagonists
Purinergic Antagonists processed this record on August 16, 2017